BACKGROUND: Obesity is an increasing health problem worldwide. The intragastric balloon as a temporary endoscopic treatment of obesity can play an important role among the aforementioned group of obese individuals. It can also be used as a preoperative test before subjecting patients to restrictive bariatric surgery. Furthermore, the intragastric device may be applied to patients affected by severe obesity as a "bridge treatment" before they undergo major surgery in order to reduce chances of operation-related risks. To date, there are insufficient data in the literature on the long-term results of the intragastric balloon. METHODS: Our study includes an analysis of our experience with Heliosphere® BAG from 2006 through to 2010, concerning early weight loss and weight loss maintenance over at least 18 months since the device's removal. The 32 patients who completed the 6-month treatment had recorded a mean weight loss of 12.66 kg and a mean overweight loss of 24.37 % (SD, 12.74). RESULTS: A total of 16 patients are subjected to an 18-month follow-up. Their pretreatment and long-term body mass index (BMI) were calculated: 6 months later, when devices were removed, they showed a mean weight of 99.75 kg (SD, 17.90; p < 0.001) and a mean weight loss of 13.62 kg and 26.14 % (SD, 12.79). 18 months after removing Heliosphere® BAG, the 16 patients' mean BMI was 37.28 kg/m² (SD, 5.41; p = 0.004), with a mean weight of 103.56 kg (SD 17.25; p = 0.0125), and a mean weight loss of 9.8 kg or 18.2 % (SD, 12.07). CONCLUSIONS: Heliosphere® BAG enables modest short-term weight loss with little side effects, although mid/long-term follow-up may entail partial weight gain. We believe it can be considered a useful bridge treatment in bariatric surgery in order to reduce chances of preoperative risks.
BACKGROUND:Obesity is an increasing health problem worldwide. The intragastric balloon as a temporary endoscopic treatment of obesity can play an important role among the aforementioned group of obese individuals. It can also be used as a preoperative test before subjecting patients to restrictive bariatric surgery. Furthermore, the intragastric device may be applied to patients affected by severe obesity as a "bridge treatment" before they undergo major surgery in order to reduce chances of operation-related risks. To date, there are insufficient data in the literature on the long-term results of the intragastric balloon. METHODS: Our study includes an analysis of our experience with Heliosphere® BAG from 2006 through to 2010, concerning early weight loss and weight loss maintenance over at least 18 months since the device's removal. The 32 patients who completed the 6-month treatment had recorded a mean weight loss of 12.66 kg and a mean overweight loss of 24.37 % (SD, 12.74). RESULTS: A total of 16 patients are subjected to an 18-month follow-up. Their pretreatment and long-term body mass index (BMI) were calculated: 6 months later, when devices were removed, they showed a mean weight of 99.75 kg (SD, 17.90; p < 0.001) and a mean weight loss of 13.62 kg and 26.14 % (SD, 12.79). 18 months after removing Heliosphere® BAG, the 16 patients' mean BMI was 37.28 kg/m² (SD, 5.41; p = 0.004), with a mean weight of 103.56 kg (SD 17.25; p = 0.0125), and a mean weight loss of 9.8 kg or 18.2 % (SD, 12.07). CONCLUSIONS: Heliosphere® BAG enables modest short-term weight loss with little side effects, although mid/long-term follow-up may entail partial weight gain. We believe it can be considered a useful bridge treatment in bariatric surgery in order to reduce chances of preoperative risks.
Authors: G Galloro; G D De Palma; C Catanzano; M De Luca; C de Werra; G Martinelli; A Romano; P Forestieri Journal: Obes Surg Date: 1999-02 Impact factor: 4.129
Authors: Melinda A Maggard; Lisa R Shugarman; Marika Suttorp; Margaret Maglione; Harvey J Sugerman; Harvey J Sugarman; Edward H Livingston; Ninh T Nguyen; Zhaoping Li; Walter A Mojica; Lara Hilton; Shannon Rhodes; Sally C Morton; Paul G Shekelle Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391
Authors: J Herve; C H Wahlen; A Schaeken; B Dallemagne; J M Dewandre; S Markiewicz; B Monami; J Weerts; C Jehaes Journal: Obes Surg Date: 2005 Jun-Jul Impact factor: 4.129
Authors: José A Sallet; João B Marchesini; Dyker S Paiva; Keila Komoto; Carlos E Pizani; Maurélio L B Ribeiro; Pablo Miguel; Alvaro M Ferraz; Paulo C Sallet Journal: Obes Surg Date: 2004-08 Impact factor: 4.129
Authors: Nicolas V Christou; John S Sampalis; Moishe Liberman; Didier Look; Stephane Auger; Alexander P H McLean; Lloyd D MacLean Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Mohammed I Yasawy; Abdulaziz A Al-Quorain; Anas M Hussameddin; Zakia M Yasawy; Raid M Al-Sulaiman Journal: J Family Community Med Date: 2014-09
Authors: Marek Buzga; Tomas Kupka; Milan Siroky; Habib Narwan; Evzen Machytka; Pavol Holeczy; Zdeněk Švagera Journal: Wideochir Inne Tech Maloinwazyjne Date: 2016-11-29 Impact factor: 1.195
Authors: Omar Alqabandi; Yousef Almutawa; Dana AlTarrah; Mufarrej Alhajeri; Mohammad H Jamal; Sulaiman Almazeedi Journal: Int J Surg Case Rep Date: 2020-08-29
Authors: Robert Drozdowski; Mariusz Wyleżoł; Mariusz Frączek; Piotr Hevelke; Marcin Giaro; Paweł Sobański Journal: Wideochir Inne Tech Maloinwazyjne Date: 2013-10-11 Impact factor: 1.195